A case report on Multisystem Inflammatory Syndrome in Children (MIS-C) with myocarditis
Department Of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Maryamuttom, Thiruvanathapuram, Kerala, India.
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2024, 18(01), 193–195.
Article DOI: 10.30574/wjbphs.2024.18.1.0176
Publication history:
Received on 22 February 2024; revised on 03 April 2024; accepted on 06 April 2024
Abstract:
Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious condition that can occur after a SARS-CoV-2 infection, commonly known as COVID-19. It involves fever, organ dysfunction, and increased inflammation markers. It was initially described as a post- infection complication of SARS-CoV-2 virus. With the development of vaccines and the efforts to control the spread of the virus, the incidence of MIS-C has decreased. There is no specific test to diagnosis a patient with this condition For patients with symptoms of MIS-C, clinicians perform a thorough evaluation, which may include blood tests, scans etc. Patients are also tested for the presence of antibodies to SARS-CoV2, the virus that causes COVID-19. When it comes to the treatment of Multisystem Inflammatory Syndrome in Children (MIS-C), it typically involves a multidisciplinary approach and may vary depending on the severity of the condition. Treatment often includes hospitalization for close monitoring and supportive care. This can involve intravenous fluids, medications to reduce inflammation, and management of specific organ complications. In some cases, additional interventions such as immunoglobulin therapy or steroids may be used.
Keywords:
MIS-C; (Multi-system inflammatory Syndrome in children); COVID-19; SARS-COV-2 (Severe acute respiratory syndrome coronavirus 2); IVIG (Intravenous immune globulin); CRP (C-reative protein)
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0